We're not gonna lieWednesdays at the J.P. Morgan Healthcare Conference feel a bit anticlimactic. Two days of meetings, presentations, panels and cocktail hours are past, and we can see the end in sight.

But that doesn't mean the action has come to a halt. Indeed, we picked up some unprecedented talk from AbbVie CEO Rick Gonzalez first thing Wednesday morning, and by day's end had heard some even bigger numbers from a GlaxoSmithKline vaccines exec.

Now, our JPM on-site team is dispersing, recapping and digging through notebooks for quotes that captured the whirlwind conference-in-progress. Here's what we heardand what we're thinkingafter Day 3.

Artificial Intelligence in the Pharma Industry

How far has the adoption of AI technology come in Life Sciences? Share your thoughts in this brief, 8-minute survey. Let your voice be heard.

Missed our previous roundups? Here areDay 1 and Day 2. And check out our collectedJPM coverage: FierceBiotech's here and FiercePharma's here.

GlaxoSmithKline and Pfizer seem to have contradictory visions for their consumer health joint venture. During a Tuesday presentation, Pfizer chief Albert Bourla said he believes the JV is heading toward an IPO within three to four years in a move that provides the New York pharma a clear exit strategy. Maybe not, GSKs chief strategy officer David Redfern saidin an interview with Bloomberg the following day. "And its entirely our decision, Redfern said. Story

At Wednesdays first presentation, AbbVie CEO Richard Gonzalez talked up the potential of two thedrugmakersnew immunology launchesSkyriziandRinvoq. While only approved in psoriasis and rheumatoid arthritis right now, respectively, Gonzalez said he expects the meds to pick up newindications toeventually match or best Humira, AbbVies almost-$20 billionmegablockbuster. If pricing holds steady, he could envision the meds reaching $20 billion in sales or more, easily picking up where Humira leaves off as biosimilars enter the U.S.in 2023. Story

GSKsShingrixgenerated blockbuster sales quickly after its launch, but numberstouted by thedrugmakerthis weekshow the size of the remaining opportunityand how much supply constraints have held the rollout back.The company figures a massive 115 million people in the U.S. alone would be eligible for Shingrix,GSKs vaccines presidentRoger Connor toldFiercePharma at JPM. The company'slooking everywhere to increase capacity, but its started to hit a bottleneck," with true relief several years away. Story

Amarin's been revving up for Vascepa's big CVlaunch in the U.S., and now thatAstraZenecas Epanova flopped a major trial, its field is clear of competitors. In Europe, Vascepa is still awaiting its regulatory review for CV risk reduction, but that hasn't stoppedother drugmakers from sniffing around for possible licensing opportunities, CEO John Thero told investors Wednesday. Not interested, Thero saidat least not yet. Amarin sees more value in waiting out the regulatory process before considering a deal. Its still a bit premature to get too far along in these conversations as we think the value will increase as the regulatory process proceeds in Europe, he said. Story

MichaelGoettler, CEO-to-be of the newViatris, said the combination of Mylan and Upjohn will have global scale and geographic reach, and will be a partner of choice for midsizeddrugmakersseeking to reach new markets. The combination makes sense because together the companies will have a sustainable and diverse portfolio,plusstrong commercial capabilities and financialperformance,Goettlersaid.

See more here:
JPM, Day 3: AbbVie duo's $20B ambitions, GSK and Pfizer's what-next moment and Amarin's clear runway - FiercePharma